Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

NCT05019534 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

Interventions

DRUG: Vemurafenib Oral Tablet [Zelboraf]
DRUG: Cetuximab Injection [Erbitux]
DRUG: Camrelizumab

Sponsor

West China Hospital